Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    Medical Dialogues Bureau
    Medical Dialogues Bureau

      Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers.  Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here

      • Home
      • Medical Dialogues...

      Articles By : Medical Dialogues Bureau

      Lupin gets USFDA nod for generic version of Edecrin tablets to treat Edema in US

      Lupin gets USFDA nod for generic version of Edecrin tablets to treat Edema in US

      Medical Dialogues Bureau10 Sept 2019 9:45 AM IST
      Lupin has received US Food and Drug Administration (USFDA) approval for Ethacrynic Acid tablets, a generic version of Bausch Health's Edecrin tablets,...
      India, China to cooperate in RnD for promoting Indian generic drugs, Chinese APIs

      India, China to cooperate in RnD for promoting Indian generic drugs, Chinese APIs

      Medical Dialogues Bureau10 Sept 2019 9:30 AM IST
      The working group on pharmaceuticals decided that both sides should explore cooperation for promoting Indian generic drugs and Chinese APIs (raw...
      Eli Lilly drug Selpercatinib shrinks tumours in lung cancer trial

      Eli Lilly drug Selpercatinib shrinks tumours in lung cancer trial

      Medical Dialogues Bureau10 Sept 2019 9:15 AM IST
      Eli Lilly's drug, now called selpercatinib, is intended for patients with rare RET abnormalities, which occur in about 2% of non-small cell lung...
      Axon Neuroscience indicates tentative Alzheimers drug hope

      Axon Neuroscience indicates tentative Alzheimers drug hope

      Medical Dialogues Bureau10 Sept 2019 9:00 AM IST
      Axon Neuroscience said its AADvac1 drug, which targets pathological changes in the brain to the so-called tau protein that is a hallmark of the...
      Incorporate Good Distribution Practices guidelines as separate Schedule in Drugs and Cosmetics Rules, 1945: DTAB recommendation

      Incorporate Good Distribution Practices guidelines as separate Schedule in Drugs and Cosmetics Rules, 1945: DTAB recommendation

      Medical Dialogues Bureau9 Sept 2019 3:56 PM IST
      New Delhi: In a move to provide quality drugs to patients, the Drugs Technical Advisory Board (DTAB) has recently recommended to include provisions on...
      Shilpa Medicare gets 2 USFDA observations for Telangana facility

      Shilpa Medicare gets 2 USFDA observations for Telangana facility

      Medical Dialogues Bureau9 Sept 2019 11:50 AM IST
      The US Food and Drug Administration (USFDA) inspected the company's finished dosage formulation facility located at Pharmaceutical Formulations SEZ,...
      Aurobindo Pharma recalls 2352 bottles of Simvastatin tablets over labelling issue

      Aurobindo Pharma recalls 2352 bottles of Simvastatin tablets over labelling issue

      Medical Dialogues Bureau9 Sept 2019 9:45 AM IST
      The reason for the recall of lipid-lowering Simvastatin tablets is "Labeling; incorrect or missing lot and/or exp date; some bottles labelled with lot...
      AstraZeneca Imfinzi shows to increase survival in aggressive lung cancer

      AstraZeneca Imfinzi shows to increase survival in aggressive lung cancer

      Medical Dialogues Bureau9 Sept 2019 9:30 AM IST
      Imfinzi, when combined with chemotherapy, resulted in a median 13 months survival in a late-stage small cell lung cancer trial, AstraZeneca said,...
      Amgen drug AMG510 shrinks lung cancer tumours in half of patients in early-stage trial

      Amgen drug AMG510 shrinks lung cancer tumours in half of patients in early-stage trial

      Medical Dialogues Bureau9 Sept 2019 9:15 AM IST
      Patients who responded to the drug AMG510 have been treated for a median of 15 weeks, but the median duration of response has not been reached,...
      Purdue Pharma expected to file for bankruptcy post opioid talks fail

      Purdue Pharma expected to file for bankruptcy post opioid talks fail

      Medical Dialogues Bureau9 Sept 2019 9:00 AM IST
      CLEVELAND: OxyContin maker Purdue Pharma is expected to file for bankruptcy after settlement talks over the nation's deadly overdose crisis hit an...
      Novo Nordisk in race with rivals Sanofi, Eli Lilly; to offer generic diabetes drug at 50pc discount

      Novo Nordisk in race with rivals Sanofi, Eli Lilly; to offer generic diabetes drug at 50pc discount

      Medical Dialogues Bureau8 Sept 2019 9:45 AM IST
      Novo will offer a generic version of its most heavily prescribed insulin drug Novolog, used by about a million U.S. patients, at a 50% discount...
      Boehringer Ingelheim gets USFDA nod for Ofev capsules to treat lung disorder

      Boehringer Ingelheim gets USFDA nod for Ofev capsules to treat lung disorder

      Medical Dialogues Bureau8 Sept 2019 9:30 AM IST
      Ofev capsule is aimed at slowing the rate of decline in pulmonary function in adults with interstitial lung disease associated with systemic...
      PrevNext

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok